Recombinant human-derived hyaluronidase has been reported to have the advantage of no risk of viral infection unlike bovine-derived hyaluronidase. Bovine-derived hyaluronidase and recombinant human-derived hyaluronidase were used for oocyte denudation and the results were compared. ICSI patients from whom four or more oocytes were collected between August 2008 and December 2008 were investigated, and a total of 376 oocytes were collected from 39 subjects. The oocytes were divided into groups based on treatment: bovine hyaluronidase (group A), and recombinant hyaluronidase (group B). The time required for oocyte denudation was slightly longer in group B than in group A, but there were no significant differences between groups A and B in the fertilization rate (70.9% vs 68.0%), the denaturation rate (9.5% vs 7.8%), the division rate (92.4% vs 97.1%), the rate of good quality embryos per embryo development (63.9% vs 71.3%), the rate of blastocyst formation (41.7% vs 45.7%), or the rate of good quality blastocysts per blastocyst formation on day 5 (25.0% vs 44.8%).
You have requested a machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Neither BioOne nor the owners and publishers of the content make, and they explicitly disclaim, any express or implied representations or warranties of any kind, including, without limitation, representations and warranties as to the functionality of the translation feature or the accuracy or completeness of the translations.
Translations are not retained in our system. Your use of this feature and the translations is subject to all use restrictions contained in the Terms and Conditions of Use of the BioOne website.
Vol. 27 • No. 2